Immunocore doses first subject in gastrointestinal cancer therapy trial
Immunocore Holdings has dosed the first subject in a multicentre Phase I/II trial of IMC-R117C, a PIWIL1-targeted immunotherapy, for treating…
Gastrointestinal
-
-
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting…
-
Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies
US-based biotechnology company Spyre Therapeutics has begun dosing healthy volunteers in Phase I studies of two investigational monoclonal antibodies. The…
-
Takeda Canada co-sponsors grant to boost IBD clinical research
Takeda Canada has co-sponsored the Canadian Inflammatory Bowel Disease Research Consortium (CIRC) PIONEER Grant to boost clinical research efforts. The…
-
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
Johnson & Johnson (J&J) and Eli Lilly have both revealed the efficacy of their interleukin-23 (IL-23) inhibitors to treat Crohn’s…
-
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug
US-based biopharmaceutical company Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra (resmetirom), a drug candidate for compensated…
-
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Eli Lilly has released histological data from the Phase III VIVID-1 trial showing that its Crohn’s disease therapy Omvoh (mirikizumab) was…
-
Clario partners with PathAI to enhance efficiency in GI clinical trials
Clario has announced a strategic partnership with AI-powered digital pathology solution provider PathAI to offer an integrated solution for enhancing…
-
Implantica’s anti-reflux device shows positive two-year results
Implantica has unveiled positive two-year results for its RefluxStop device, an implant designed to manage gastro-oesophageal reflux disease (GORD). Results…
-
ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
ALX Oncology has revealed topline data from its Phase II ASPEN-06 clinical trial, indicating that evorpacept, in combination with standard…
